Supplementary Figure S1



Supplementary Figure S1. DNT expression of inhibitory KIR and subset cytotoxicity markers. a. DNT expression of CD94 and KIR receptors on eight donors. Dot represents individual donor and % expression of molecule amongst DNT cells. b. DNT subset analysis of cytotoxicity receptors. Filled histograms represent isotype controls, dotted lines histograms represent $\alpha\beta$ -DNTs and solid lines histograms represent $\gamma\delta$ -DNTs. Numbers shown are the MFI values..



Supplementary Figure S2. Effect of blocking TCR and HLA on DNT-mediated lysis of lung cancer cells. A. Anti-TCR $\gamma\delta$ antibody was used to block DNT-mediated cytolysis towards various cancer cell lines. B. Expression of HLA molecules known to interact with KIRs on lung cancer cells. C. Anti-HLA antibodies and anti-CD94 on DNT-mediated cytolysis of lung cancer cells.



Mechanisms of DNT mediated cytotoxicity of lung cancer and AML3. a. DNTs were cocultured with NSCLC cell lines in the presence of anti-IFN γ antibody. % inhibition calculated relative to isotype control. b. DNT were treated with CMA then cocultured with acute myeloid leukemia cell line AML3. % inhibition calculated relative to DMSO vehicle treated cells.



IL-15 activates DNTs but has no effect on some effector molecules. a, b Filled histograms represent isotype controls, dotted line histograms represent DNTs in the absent of IL-15 and solid line histograms represent DNTs in the present of IL-15. **c** TNF α in the supernatant of DNTs stimulated with IL-2 in the presence of absence of IL-15 was measured by ELISA.



The cytotoxicity of DNTs against NSCLC cells is not dependent on some effector molecules. Anti-NKp44 (a) or anti-IFN γ (b) antibody was added to DNTs and NSCLC cells co-cultures. The percent inhibition of cytotoxicity was calculated relative to isotype control.

Supplementary Table S1

Histological classification and common mutation found within primary established NSCLC cell lines.

Primary cell	Histology	Driver mutation*	Patient
line ID			(Male/Female)
12	adenocarcinoma (ADC)	BRAF	F
178	adenocarcinoma (ADC)	no mutation	F
426	adenocarcinoma (ADC)	not tested	F
277	adenocarcinoma (ADC)	EGFR	М
655	adenocarcinoma (ADC)	no mutation	М
229	adenocarcinoma (ADC)	no mutation	М
239	adenocarcinoma (ADC)	no mutation	М
137	adenocarcinoma (ADC)	EGFR	F